Public drug plans shouldn’t cover new Alzheimer’s drug, Canada’s Drug Agency recommends

3mon 28d ago by ibbit.at/u/rss in medicine@lemmy.ca from www.theglobeandmail.com

Sara Mitchell, a cognitive neurologist at Sunnybrook Health Sciences Centre in Toronto, said the absence of a recommendation from CDA on lecanemab coverage would “mean a lot of despair for a lot of people.”

From The Globe and Mail via this RSS feed